Deal Snapshot
CHARLES RIVER LABORATORIES ACQUIRES UK CRO KWS BIOTEST
Friday 12 January 2018

Massachusetts, US-based pre-clinical and clinical laboratory services provider Charles River Laboratories International, Inc. (NYSE: CRL) has acquired UK-based contract research organisation KWS BioTest, the company said.
KWS BioTest specialises in in vitro and in vivo discovery testing services for immuno-oncology and inflammatory and infectious diseases. The addition of KWS enhances Charles River's discovery expertise, with complementary offerings that provide our clients with additional tools in the active therapeutic research areas of oncology and immunology.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 12/01/2018
Target: KWS BioTest
Country: UK
Sector: Pharmaceuticals
Type: Corporate acquisition
Financing:
Status: Closed
Vendor:
Buyer: Charles River Laboratories
Comment:
Terms of the deal were not disclosed

Options